GlassScriptPhysician profile
Alberto R Sanchez
NPI 1659376259
$1,364.56
in general payments reported to CMS, 2019-2025
23 companies · $45.00 in 2025
The $45.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $344 · 2021: $14.03 · 2024: $22.50 · 2025: $45.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $45.00 · Food and Beverage: $22.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $45.00 |
| Food and Beverage | $22.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $285.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.37 | 2019-2021 | |
| Abbvie INC. | $177.78 | 2019-2020 | |
| Novo Nordisk INC | $85.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $77.51 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $66.09 | 2019 | |
| Amarin Pharma, INC. | $61.03 | 2019 | |
| Lilly USA, LLC | $57.56 | 2019-2025 | |
| Indivior INC. | $46.51 | 2019 | |
| Glaxosmithkline, LLC. | $41.36 | 2019 | |
| Abbott Laboratories | $35.31 | 2019 | |
| Astellas Pharma US INC | $29.97 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.57 | 2019 | |
| Amgen INC. | $22.50 | 2024 | Otezla, Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.85 | 2019 | |
| Avion Pharmaceuticals | $19.62 | 2019 | |
| Therapeuticsmd, INC. | $14.21 | 2020 | |
| Duchesnay USA Incorporated | $13.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.58 | 2020 | |
| Eisai INC. | $11.24 | 2019 | |
| Lupin INC. | $11.20 | 2019 | |
| Pfizer INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.